407 related articles for article (PubMed ID: 25063251)
1. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete.
Zhou J; Li J; Yan P; Ye YH; Peng W; Wang S; Wang XT
Placenta; 2014 Sep; 35(9):691-5. PubMed ID: 25063251
[TBL] [Abstract][Full Text] [Related]
2. Increased level of cell-free placental mRNA in a subgroup of placenta previa that needs hysterectomy.
Miura K; Miura S; Yamasaki K; Yoshida A; Yoshiura K; Nakayama D; Niikawa N; Masuzaki H
Prenat Diagn; 2008 Sep; 28(9):805-9. PubMed ID: 18646248
[TBL] [Abstract][Full Text] [Related]
3. Human placental lactogen mRNA in maternal plasma play a role in prenatal diagnosis of abnormally invasive placenta: yes or no?
Li J; Zhang N; Zhang Y; Hu X; Gao G; Ye Y; Peng W; Zhou J
Gynecol Endocrinol; 2019 Jul; 35(7):631-634. PubMed ID: 30784325
[No Abstract] [Full Text] [Related]
4. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study.
Berezowsky A; Pardo J; Ben-Zion M; Wiznitzer A; Aviram A
Fetal Diagn Ther; 2019; 46(3):187-192. PubMed ID: 30726846
[TBL] [Abstract][Full Text] [Related]
5. Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta.
El Behery MM; Rasha L E; El Alfy Y
Int J Gynaecol Obstet; 2010 Apr; 109(1):30-3. PubMed ID: 20070963
[TBL] [Abstract][Full Text] [Related]
6. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study.
Samuel A; Bonanno C; Oliphant A; Batey A; Wright JD
Prenat Diagn; 2013 Nov; 33(11):1050-3. PubMed ID: 23836321
[TBL] [Abstract][Full Text] [Related]
7. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis.
Jauniaux E; Bhide A
Am J Obstet Gynecol; 2017 Jul; 217(1):27-36. PubMed ID: 28268196
[TBL] [Abstract][Full Text] [Related]
8. Maternal serum markers, characteristics and morbidly adherent placenta in women with previa.
Lyell DJ; Faucett AM; Baer RJ; Blumenfeld YJ; Druzin ML; El-Sayed YY; Shaw GM; Currier RJ; Jelliffe-Pawlowski LL
J Perinatol; 2015 Aug; 35(8):570-4. PubMed ID: 25927270
[TBL] [Abstract][Full Text] [Related]
9. Decreased placental and maternal serum TRAIL-R2 levels are associated with placenta accreta.
Oztas E; Ozler S; Ersoy AO; Ersoy E; Caglar AT; Uygur D; Yucel A; Ergin M; Danisman N
Placenta; 2016 Mar; 39():1-6. PubMed ID: 26992667
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of cell-free human placental lactogen mRNA at 28-32 gestational weeks in plasma of pregnant women with placenta previa and invasive placenta.
Kawashima A; Sekizawa A; Ventura W; Koide K; Hori K; Okai T; Masashi Y; Furuya K; Mizumoto Y
Reprod Sci; 2014 Feb; 21(2):215-20. PubMed ID: 23744883
[TBL] [Abstract][Full Text] [Related]
11. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.
Zelop C; Nadel A; Frigoletto FD; Pauker S; MacMillan M; Benacerraf BR
Obstet Gynecol; 1992 Oct; 80(4):693-4. PubMed ID: 1383899
[TBL] [Abstract][Full Text] [Related]
12. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
Büke B; Akkaya H; Demir S; Sağol S; Şimşek D; Başol G; Barutçuoğlu B
J Matern Fetal Neonatal Med; 2018 Jan; 31(1):59-62. PubMed ID: 28027672
[TBL] [Abstract][Full Text] [Related]
13. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation.
Thompson O; Otigbah C; Nnochiri A; Sumithran E; Spencer K
BJOG; 2015 Sep; 122(10):1370-6. PubMed ID: 25639820
[TBL] [Abstract][Full Text] [Related]
14. Increased Levels of Cell-Free miR-517a and Decreased Levels of Cell-Free miR-518b in Maternal Plasma Samples From Placenta Previa Pregnancies at 32 Weeks of Gestation.
Hasegawa Y; Miura K; Higashijima A; Abe S; Miura S; Yoshiura K; Masuzaki H
Reprod Sci; 2015 Dec; 22(12):1569-76. PubMed ID: 26040940
[TBL] [Abstract][Full Text] [Related]
15. Placenta previa, placenta accreta, and vasa previa.
Oyelese Y; Smulian JC
Obstet Gynecol; 2006 Apr; 107(4):927-41. PubMed ID: 16582134
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of abnormally invasive placenta.
Al-Khan A; Youssef YH; Feldman KM; Illsley NP; Remache Y; Alvarez-Perez J; Mannion C; Alvarez M; Zamudio S
Placenta; 2020 Feb; 91():37-42. PubMed ID: 32174305
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound accuracy in prenatal diagnosis of abnormal placentation of posterior placenta previa.
Garofalo A; Pilloni E; Alemanno MG; Garofalo G; Sciarrone A; Todros T; Viora E
Eur J Obstet Gynecol Reprod Biol; 2019 Nov; 242():86-91. PubMed ID: 31574389
[TBL] [Abstract][Full Text] [Related]
18. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders.
Penzhoyan GA; Makukhina TB
J Perinat Med; 2019 Dec; 48(1):21-26. PubMed ID: 31730533
[TBL] [Abstract][Full Text] [Related]
19. Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa.
Melcer Y; Jauniaux E; Maymon S; Tsviban A; Pekar-Zlotin M; Betser M; Maymon R
Am J Obstet Gynecol; 2018 Apr; 218(4):443.e1-443.e8. PubMed ID: 29353034
[TBL] [Abstract][Full Text] [Related]
20. First trimester serum PAPP-A is associated with placenta accreta: a retrospective study.
Wang F; Chen S; Wang J; Wang Y; Ruan F; Shu H; Zhu L; Man D
Arch Gynecol Obstet; 2021 Mar; 303(3):645-652. PubMed ID: 33515274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
